Skip to content

Suture Fixation System Versus Tendonous Reconstruction in Carpometacarpal (CMC) Arthroplasty

Suture Fixation System Versus Tendonous Reconstruction in Thumb Carpometacarpal Arthroplasty: a Randomized Controlled Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01121874
Enrollment
53
Registered
2010-05-12
Start date
2010-04-12
Completion date
2012-07-25
Last updated
2018-08-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thumb Carpometacarpal Arthritis

Keywords

CMC arthritis, thumb carpometacarpal arthritis, basal joint arthritis, thumb CMC arthritis

Brief summary

Thumb carpometacarpal (CMC) arthritis affect 1 in 4 females and 1 in 12 males. Patients who fail to respond to conservative treatment may benefit from surgery; however, controversy exists over the most effective surgical technique. A popular technique, ligament reconstruction with tendon interposition (LRTI) involves a trapeziectomy, followed by reconstruction of the palmar oblique ligament using a harvested flexor tendon from the wrist. We believe that use of a suture fixation system to reconstruct the palmar oblique ligament, instead of harvesting a wrist tendon, may provide a superior repair. The objective of this study is to compare functional outcome measurements among patients who receive CMC arthroplasty using a suture fixation system (investigational group) to those who receive LRTI surgery (control group). We hypothesize that patients in the investigational group will demonstrate superior functionality, compared to patients in the control group.

Interventions

PROCEDURELigament reconstruction with suture fixation system

CMC arthroplasty consisting of reconstruction of the palmar oblique ligament using a suture fixation system

PROCEDURELigament Reconstruction with Tendon Interposition (LRTI)

commonly performed CMC arthroplasty technique, consisting of a trapeziectomy, followed by palmar oblique ligament reconstruction using a harvested flexor tendon from the wrist.

Sponsors

J&M Shuler
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Male or female patients aged \>18. * Eaton Stage III or IV CMC arthritis * Failure to respond to conservative treatment

Exclusion criteria

* Previous surgical interventions on that thumb * Upper extremity neurological dysfunction * Inability to effectively communicate with the research staff, due to hearing impairment, cognitive impairment, or a language barrier * Unwilling or unable to provide written informed consent

Design outcomes

Primary

MeasureTime frameDescription
Overall functionalityBaselineFunctionality will be assessed using the Disabilities of the Arm, Shoulder, and Hand (DASH) questionnaire, which assesses functionality of the upper extremity, and Short Form 36 (SF-36) health outcomes assessment, which quantifies global functionality (not specific to the upper extremity).
Overall Functionality6 wks

Secondary

MeasureTime frameDescription
Range of motionBaseline, 6 wks, 3 mos, 6 mos, 12 mos, 24 mosRange of motion (ROM) will be assessed via radial and palmar abduction (degrees) and opposition (cm).
Analog pain scaleBaseline, 2 wks, 6 wks, 3 mos, 6 mos, 12 mos, 24 mosPain will be assessed using the visual analog pain scale, which asks the patient to rate their pain on a scale from 1 to 10.
Scaphometacarpal distanceBaseline, 6 wks, 3 mos, 6 mos, 12 mos, 24 mosDistance between the distal pole of the scaphoid and the proximal aticular surface of the metacarpal. Taken in stressed and relaxed views
Operative timeBaseline, 6 wks, 3 mos, 6 mos, 12 mos, 24 mosOperative time in minutes
Strength measuresBaseline, 6 wks, 3 mos, 6 mos, 12 mos, 24 mosStrength will be assessed via key and tip pinch strength and grip strength, using a dynamometer

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026